The UK market has been flat over the last week but is up 11% over the past year, with earnings expected to grow by 14% per annum in the coming years. While ‘penny stocks’ might seem like a term from yesteryear, they continue to offer intriguing investment opportunities by highlighting smaller or newer companies that can provide growth at accessible price points. By focusing on those with strong balance sheets and solid fundamentals, investors can uncover hidden gems that combine stability with potential upside.

Name

Share Price

Market Cap

Financial Health Rating

Tristel (AIM:TSTL)

£3.875

£189.41M

★★★★★★

ME Group International (LSE:MEGP)

£2.04

£791.19M

★★★★★★

Next 15 Group (AIM:NFG)

£4.095

£402.8M

★★★★☆☆

Supreme (AIM:SUP)

£1.55

£177.83M

★★★★★★

FRP Advisory Group (AIM:FRP)

£1.325

£316.35M

★★★★★★

Stelrad Group (LSE:SRAD)

£1.50

£192.3M

★★★★★☆

Luceco (LSE:LUCE)

£1.53

£227.33M

★★★★★☆

Ultimate Products (LSE:ULTP)

£1.395

£118.72M

★★★★★★

Serabi Gold (AIM:SRB)

£0.935

£68.62M

★★★★★★

Integrated Diagnostics Holdings (LSE:IDHC)

$0.45

$269.74M

★★★★★★

Click here to see the full list of 467 stocks from our UK Penny Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Begbies Traynor Group plc offers professional services to businesses, advisors, corporations, and financial institutions in the UK and has a market cap of £143.94 million.

Operations: The company’s revenue is derived from two main segments: Property Advisory, contributing £40.36 million, and Business Recovery and Advisory, generating £96.38 million.

Market Cap: £143.94M

Begbies Traynor Group, with a market cap of £143.94 million, derives revenue from Property Advisory (£40.36M) and Business Recovery and Advisory (£96.38M). The company has managed to reduce its debt-to-equity ratio significantly over the past five years and maintains a satisfactory net debt level at 1.8%. Despite negative earnings growth recently, analysts forecast a robust 50.24% annual earnings increase going forward. The board’s experience adds stability, but recent significant insider selling could be concerning for investors. A new share buyback program aims to repurchase up to 10% of issued shares by December 2025, potentially supporting the stock price.

AIM:BEG Revenue & Expenses Breakdown as at Oct 2024

AIM:BEG Revenue & Expenses Breakdown as at Oct 2024

Simply Wall St Financial Health Rating: ★★★★☆☆

Story Continues